NASDAQ: COCPCocrystal Pharma Inc Stock
$2.25-0.11 (-4.66%)
Updated May 31, 2024
COCP Price
$2.25
Fair Value Price
$2.55
Market Cap
$22.89M
52 Week Low
$1.33
52 Week High
$3.29
P/E
-1.36x
P/B
1.01x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$16.75M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.18
Operating Cash Flow
-$16M
Beta
0.14
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
COCP Overview
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that has completed Phase II a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX Inc. The company is headquartered in Bothell, Washington.
Zen Score
–
Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how COCP scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
COCP ($2.25) is undervalued by 11.64% relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
COCP ($2.25) is not significantly undervalued (11.64%) relative to our estimate of its Fair Value price of $2.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
COCP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more COCP due diligence checks available for Premium users.
Be the first to know about important COCP news, forecast changes, insider trades & much more!
COCP News
Valuation
COCP fair value
Fair Value of COCP stock based on Discounted Cash Flow (DCF)
Price
$2.25
Fair Value
$2.55
Undervalued by
11.64%
COCP ($2.25) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
COCP ($2.25) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
COCP is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
COCP price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.36x
Industry
-14.17x
Market
28.44x
COCP price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.01x
Industry
6.04x
COCP is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
COCP's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.0M
Profit Margin
0%
COCP's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$26.5M
Liabilities
$4.0M
Debt to equity
0.18
COCP's short-term assets ($24.49M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
COCP's short-term assets ($24.49M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
COCP's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
COCP's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.5M
Investing
-$8.0k
Financing
$0.0
COCP's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
COCP vs Biotech Stocks
Cocrystal Pharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.